A new non-opioid painkiller, suzetrigine, has just been approved by the US drug regulator, the FDA. It is the first ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

A new non-opioid painkiller, suzetrigine , has just been approved by the US drug regulator, the FDA. It is the first non-opioid painkiller the agency ...

The FDA has approved suzetrigine, a groundbreaking non-opioid painkiller that targets pain at its source, offering a safer, ...

For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...

In 2004, a research group at Peking University First Hospital discovered a mutation in the gene coding for a sodium-channel ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

The signal is triggered by sodium rushing into the nerve ending, sending the message onward to the brain. Suzetrigine is a ...

The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.